The genetic toxicity effects of lamivudine and stavudine antiretroviral agents

Abstract

Importance of the field: The nucleoside reverse transcriptase inhibitors (NRTIs) are used in antiretroviral therapy worldwide for the treatment of HIV infections. These drugs act by blocking reverse transcriptase enzyme activity, causing pro-viral DNA chain termination. As a consequence, NRTIs could cause genomic instability and loss of heterozygosity.

Areas covered in this review: This review highlights the toxic and genotoxic effects of NRTIs, particularly lamivudine (3TC) and stavudine (d4T) analogues. In addition, a battery of short-term in vitro and in vivo systems are described to explain the potential genotoxic effects of these NRTIs as a single drug or a complexity of highly active antiretroviral therapy.

What the reader will gain: The readers will gain an understanding of a secondary effect that could be induced by 3TC and d4T treatments.

Take home message: Considering that AIDS has become a chronic disease, more comprehensive toxic genetic studies are needed, with particular attention to the genetic alterations induced by NRTIs. These alterations play a primary role in carcinogenesis and are also involved in secondary and subsequent steps of carcinogenesis.

Keywords::

• anti-HIV drugs
• genotoxicity
• lamivudine
• nucleoside reverse transcriptase inhibitors
• stavudine
• toxicity

Notes

This box summarizes key points contained in the article.